Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors : a cost-effectiveness analysis of prophylaxis with emicizumab

Tools

Camelo, Ricardo Mesquita and Barbosa, Mariana Michel and Araújo, Maiara Silva and Lúcio Muniz Jr, Roberto and Guerra Jr, Augusto Afonso and Godman, Brian and Rezende, Suely Meireles and Acurcio, Francisco de Assis and Martin, Antony P. and Alvares-Teodoro, Juliana (2023) Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors : a cost-effectiveness analysis of prophylaxis with emicizumab. Value in Health Regional Issues, 34. pp. 31-39. ISSN 2212-1102 (https://doi.org/10.1016/j.vhri.2022.10.007)

[thumbnail of Camelo-etal-VHRI-2022-Economic-evaluation-of-immune-tolerance-induction-in-children]
Preview
 Text. Filename: Camelo_etal_VHRI_2022_Economic_evaluation_of_immune_tolerance_induction_in_children.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (962kB)| Preview

Abstract

Objective: This study aimed to measure the cost-effectiveness of prophylaxis with emicizumab in PsHAhri on ITI in Brazil. Methods: A cost-effectiveness modeling analysis was used to estimate the costs per PsHAhri on ITI and the number of prevented bleedings from undertaking one intervention (prophylaxis with BpA) over another (prophylaxis with emicizumab), based on the Brazilian Ministry of Health perspective. Costs of ITI with recombinant FVIII, prophylaxis with BpA or emicizumab, and treated bleeding episodes with BpA costs were evaluated for PsHAhri who had ITI success or failure. This study was conducted with the perspective of the Brazilian Ministry of Health (payer). Results: During ITI, prophylaxis with BpA cost US $924 666/PsHAhri/ITI, whereas prophylaxis with emicizumab cost US $488 785/PsHAhri/ITI. During ITI, there was an average of 9.32 bleeding episodes/PsHAhri/ITI when BpA were used as prophylaxis and 0.67 bleeding/PsHAhri/ITI when emicizumab was used. By univariate deterministic sensitivity analysis, emicizumab remained dominant whichever variable was modified. Conclusion: In this study, prophylaxis with emicizumab during ITI is a dominant option compared with prophylaxis with BpA during ITI.

CORE (COnnecting REpositories)